Dyadic International Inc
DYAI Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.40
KIRA · Stoqly’s AI analyst, in plain words
- Dyadic International Inc had $3.1M of revenue in fiscal 2025, down 11.6% on the year before. Over five years, revenue changed +14.0% a year on average.
- Its operating margin was −232.8%, down 63.9 pts: of every 100 in sales, about −233 is left after running the business.
- Dyadic International Inc lost $7.4M in fiscal 2025.
Market cap
$14.5M
P/E
—
Revenue
$3.1M
Net income
−$7.4M
Free cash flow
—
Operating margin
−232.8%
Dyadic International Inc in 30 seconds · fiscal 2025
Are sales growing?
−11.6%
No. Sales fell 11.6% last year.
Does it make a profit?
−238.3%
No. It lost money last year.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Dyadic International Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- DYADIC INTERNATIONAL INC
- CIK
- 0001213809
Dyadic International Inc · DYAI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.4M | $2.9M | $2.9M | $3.5M | $3.1M |
| Revenue growth | 50.1% | 21.9% | −1.1% | 20.6% | −11.6% |
| Gross margin | 19.1% | 27.5% | 31.8% | 65.8% | 24.9% |
| Operating margin | −612.7% | −346.9% | −283.9% | −168.8% | −232.8% |
| Net income | −$13.1M | −$9.7M | −$6.8M | −$5.8M | −$7.4M |
| Net margin | −543.7% | −332.2% | −234.4% | −166.2% | −238.3% |
| Diluted EPS | −$0.47 | — | — | −$0.20 | −$0.23 |
| Cash | |||||
| Cash from operations | −$11.3M | −$8.1M | −$6.7M | −$4.0M | −$5.7M |
| Share count change | 1.3% | — | — | — | 11.3% |
| Debt and strength | |||||
| Cash and short-term investments | $15.7M | $5.8M | $6.5M | $9.3M | $7.3M |
| Shareholders' equity | $18.4M | $11.1M | $5.9M | $2.5M | $1.2M |
| Current ratio | 8.2x | 5.5x | 3.6x | 4.0x | 2.7x |
| Returns and quality | |||||
| Return on equity | −55.8% | −66.1% | −80.1% | −139.2% | −397.8% |
| Return on tangible equity | −71.1% | −87.8% | −115.6% | −235.2% | −597.6% |
| Piotroski F-score | 3 | 3 | 3 | 4 | 1 |
| Altman Z'' | −2.1 | −12.8 | −31.3 | −27.0 | −31.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dyadic International Inc · DYAI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.40 a share, the company is worth $14.5M.
Source: SEC EDGAR XBRL filings (CIK 0001213809). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.